3SBio Inc. logo

3SBio Inc.

Asia, Liaoning, China, Shenyang

Description

3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing.

Investor Profile

3SBio Inc. has backed more than 6 startups, with 2 new investments in the last 12 months alone. The firm has led 2 rounds, about 33% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series A, Series Unknown rounds (top funding stages).
  • Majority of deals are located in United States, China, France.
  • Strong thematic focus on Biotechnology, Medical, Therapeutics.
  • Led 1 rounds in the past year.

Stage Focus

  • Series B (33%)
  • Series A (33%)
  • Series Unknown (17%)
  • Post Ipo Debt (17%)

Country Focus

  • United States (50%)
  • China (33%)
  • France (17%)

Industry Focus

  • Biotechnology
  • Medical
  • Therapeutics
  • Health Care
  • Genetics
  • Pharmaceutical
  • Health Diagnostics
  • Nuclear
  • Biopharma
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does 3SBio Inc. frequently co-invest with?

INCE Capital
Asia, Shandong, China, Pudong
Co-Investments: 1
The Mark Foundation for Cancer Research
North America, New York, United States, New York
Co-Investments: 1
Yonghua Capital
Asia, Shanghai, China, Shanghai
Co-Investments: 1
Alexandria Venture Investments
North America, California, United States, Pasadena
Co-Investments: 1
20/20 HealthCare Partners
North America, Massachusetts, United States, Auburndale
Co-Investments: 1
OC
North America, New York, United States, New York
Co-Investments: 1
LongRiver Investments
Asia, Shanghai, China, Xuhui
Co-Investments: 1
IP
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
EV
Asia, Shanghai, China, Shanghai
Co-Investments: 1
Highlight Capital
Asia, Jiangsu, China, Nanjin
Co-Investments: 1

What are some of recent deals done by 3SBio Inc.?

NK CellTech

Zhoupu, Shanghai, China

NK CellTech is a biotechnology company that specializes in the development of innovative technologies for treatment of NK cell therapy.

BiopharmaBiotechnologyMedical
Series ANov 22, 2024
C Ray Therapeutics

Chengdu, Sichuan, China

C Ray Therapeutics develops healthcare advancements through nuclear medicine.

Health CareHealth DiagnosticsMedicalNuclear
Series ANov 17, 2024
Amount Raised: $100,000,000
Allorion Therapeutics

Natick, Massachusetts, United States

Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses.

MedicalPharmaceuticalTherapeutics
Series BMar 9, 2023
Amount Raised: $50,000,000
GenSight Biologics

Paris, Ile-de-France, France

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.

BiotechnologyGeneticsHealth CareMedical
Post Ipo DebtDec 20, 2019
Amount Raised: $16,615,804
Verseau Therapeutics

Bedford, Massachusetts, United States

Verseau focus is building a pipeline of first-in-class therapies that modulate macrophages to trigger a coordinated immune attack on cancer.

BiotechnologyTherapeutics
Series UnknownOct 21, 2019
Amount Raised: $50,000,000
Refuge Biotechnologies

Menlo Park, California, United States

Refuge Biotechnologies therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy.

BiotechnologyGeneticsHealth CareTherapeutics
Series BMay 2, 2018
Amount Raised: $25,000,000